Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 2/20 | 0.67 |
| ▸ | PI4KA | P42356 | 4/20 | 0.60 |
| ▸ | PI4K2B | Q8TCG2 | 4/20 | 0.60 |
| ▸ | PI4K2A | Q9BTU6 | 4/20 | 0.60 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.60 |
| ▸ | EGFR | P00533 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | CDK1 | P06493 | 1/20 | 0.55 |
| ▸ | XDH | P47989 | 3/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.48 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.45 |
| ▸ | PDE8A | O60658 | 3/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22411631 | 0.86 | CFTR (0.65) | CFTRPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL30331960 | 0.84 | CYP2D6 (0.58) | CFTRPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL9383398 | 0.84 | CYP2D6 (0.58) | CFTRPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL27886637 | 0.84 | PI4KA (0.64) | CFTRPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL30677365 | 0.84 | CYP2D6 (0.65) | CFTRPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL17802599 | 0.81 | CFTR (0.67) | CFTRPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL22431902 | 0.81 | CYP2D6 (0.55) | CFTRPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL17802607 | 0.80 | CFTR (1.00) | CFTRPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL1654709 | 0.78 | YTHDC1 (0.54) | CFTRPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL27388299 | 0.78 | YTHDC1 (0.70) | CYP2D6CYP2C9TSHRCYP2C19CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144838-A1 | Compounds as Inhibitors of Macrophage Migration Inhibitory Factor | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2022-05-12 | — | — | US | disclosed |
| US-20220144838-A1 | Compounds as Inhibitors of Macrophage Migration Inhibitory Factor | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2022-05-12 | — | — | US | disclosed |
| WO-2020186220-A1 | COMPOUNDS AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR | IMMUNOPHAGE BIOMEDICAL CO., LTD. (CN) | 2020-09-17 | — | — | WO | disclosed |
| US-10414768-B2 | Compounds for treating cystic fibrosis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2019-09-17 | — | — | US | disclosed |
| US-10414768-B2 | Compounds for treating cystic fibrosis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2019-09-17 | — | — | US | disclosed |
| US-20170362239-A1 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) | 2017-12-21 | — | — | US | disclosed |
| US-20170362239-A1 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) | 2017-12-21 | — | — | US | disclosed |
| US-20170362239-A1 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) | 2017-12-21 | — | — | US | disclosed |
| WO-2016087665-A2 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144838-A1 | Compounds as Inhibitors of Macrophage Migration Inhibitory Factor | MIF, MMP12, SLC11A2 | CFTR 552/4885PI4KA 1759/4885PI4K2B 1615/4885 |
| US-10414768-B2 | Compounds for treating cystic fibrosis | CFTR, ABCB11, SLC26A4 | CFTR 1/4885PI4KA 3428/4885PI4K2B 3935/4885 |
| US-20170362239-A1 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | CFTR, ABCB11, SLC26A4 | CFTR 1/4885PI4KA 3428/4885PI4K2B 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.